Karolinska Institutet is one of the world´s leading medical universities. Our mission is to contribute to the improvement of human health through research and education.
Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences.
Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.
Karolinska Institutet was founded by King Karl XIII in 1810 as an "academy for the training of skilled army surgeons". Today, Karolinska Institutet is a modern medical university and one of the foremost in the world.
With our close relationship to the clinical milieu, a well established infrastructure and a stable financial situation, Karolinska Institutet has excellent prerequisites for sustaining high quality research and education.
Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.